Dominick Colangelo has been serving as the President and CEO of Vericel Corporation since 2017. With a strong background in the biopharmaceutical industry, Colangelo has been instrumental in steering Vericel towards significant growth and success. Prior to joining Vericel, he held various leadership positions at major companies such as Integra LifeSciences, where he served as Corporate Vice President and President of the Extremity Reconstruction division. His tenure at Integra was marked by strategic initiatives that enhanced the company's market position and financial performance. At Vericel, Colangelo has been pivotal in advancing the company's mission to develop, manufacture, and market advanced cell therapies for sports medicine and severe burn care. Under his leadership, Vericel has seen the successful commercialization of key products like MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). These therapies have not only improved patient outcomes but also solidified Vericel's reputation as a leader in regenerative medicine. Colangelo's strategic vision and operational expertise have been crucial in navigating the complex landscape of biologics and ensuring that Vericel remains at the forefront of innovation in its field. Colangelo's achievements extend beyond corporate success; he is also recognized for his contributions to the broader biopharmaceutical community. He holds a Bachelor of Science degree in Mechanical Engineering from Villanova University and an MBA from Drexel University. His commitment to advancing healthcare through innovative therapies is evident in his leadership style and the culture he fosters at Vericel. As President and CEO, Colangelo continues to drive the company's growth, focusing on expanding its product portfolio and enhancing its global presence, all while maintaining a patient-centric approach.